AskBorsa
ARSign up free
EGX·Health Care & Pharmaceuticals

Glaxo Smith Kline

BIOC
Fiscal year starts in January · currency EGP · latest: Q2 2026
Next results: Q3 2026 — expected around 15 November 2026published last year on 13 November 2025Results calendar ←
305.00EGP+15.53% today1w +18.1%1m −12.9%delayed · 3 November
Net profit · 2025
213million
▲ 22.6% vs 2024
Total assets · 2025
4.5billion
▲ 23.2% vs 2024
Shareholders' equity · 2025
2.22billion
▲ 11.1% vs 2024
Operating cash flow · 2025
241million
▲ 159.6% vs 2024

Key facts

Source: annual statements 2025
  • Glaxo Smith Kline's net profit in 2025 was 213 million EGP, up 22.6% from 174 million EGP in 2024.
  • Total assets at the end of 2025 were 4.5 billion EGP, and shareholders' equity 2.22 billion EGP.
  • Operating cash flow in 2025 was positive at 241 million EGP.

Glaxo Smith Kline's Q3 2026 results are expected around 15 November — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Ask about Glaxo Smith Kline
How much did Glaxo Smith Kline's net profit grow last year?What were total assets and shareholders' equity in the latest annual balance sheet?Was operating cash flow positive in the last three years?Type your question…Ask
3 free questions a day after signing up. With Google, no password.
Annual net profit last 5 years
Net profit
155million
735million
60.46million
174million
213million
20212022202320242025

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP20212022202320242025
Income statement
Net profit155 million735 million60.46 million174 million213 million
Gross profit759 million606 million877 million1.14 billion904 million
Total assets2.42 billion3.19 billion3.56 billion3.65 billion4.5 billion
Total liabilities1.07 billion1.46 billion1.59 billion1.66 billion2.28 billion
Shareholders' equity1.36 billion1.73 billion1.97 billion2 billion2.22 billion
Total liabilities and equity2.42 billion3.19 billion3.56 billion3.65 billion4.5 billion
Operating cash flow202 million-335 million302 million-404 million241 million
Investing cash flow-35.15 million-242 million85.5 million-226 million115 million
Financing cash flow-106 million58.96 million-144 million-124 million48 million
Net change in cash51.41 million-740 million517 million-754 million404 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Q2 2026Fiscal year 2025Q4 2025Q3 2025Q2 2025Q1 2025Fiscal year 2024Q4 2024Q3 2024Q2 2024Q1 2024Fiscal year 2023Q4 2023Q3 2023Q2 2023Q1 2023Fiscal year 2022Q4 2022Q3 2022Q2 2022Q1 2022Fiscal year 2021

Financial reports (19)

2026Q2
PDF
2026Q1
PDF
2025Annual
PDF
2025Q2
PDF
2025Q3
PDF
2025Q1
PDF
2024Annual
PDF
2024Q1
PDF
2024Q2
PDF
2024Q3
PDF
2023Annual
PDF
2023Q1
PDF
2023Q2
PDF
2023Q3
PDF
2022Annual
PDF
2022Q1
PDF
2022Q2
PDF
2022Q3
PDF
2021Annual
PDF

Other companies in Health Care & Pharmaceuticals

Ranked by latest annual net profit
All companies in the sector ←
EIPICOPHAR·1.1billion+33%Ibnsina PharmaISPH·952million+55%Cleopatra Hospitals GroupCLHO·824million+14%Alexandria PharmaceuticalsAXPH·660million+1132%Memphis PharmaceuticalsMPCI·480million−5%Cairo PharmaceuticalsCPCI·444million+769%